Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors and represents the fifth most common cause of cancer-related deaths. It is associated with a poor prognosis, likely due to the tendency of the tumor for early local and distant spread. One of the major obstacles of effectively treating PDAC is the often late diagnosis. Among all options currently available for PDAC, surgical resection offers the only potential cure with 5-year survival rate of approximately 15–20 %. However, in the absence of metastatic disease, which precludes resection, assessment of vascular invasion is an important parameter for determining resectability for pancreatic cancer. The vascular involvement in patients with pancreatic carcinoma ranges between 21 and 64 %. Historically, vascular involvement has been considered a contraindication to resective cure. Meanwhile, the surgical approach of pancreatoduodenectomy (PD) combined with vascular resection and reconstruction has been widely applied in clinical practice to remove the tumor completely. Therefore, vascular invasion is no longer a surgical contraindication and the rate of surgical resection has greatly increased. Moreover, PD combined with vascular resection can account for 20 to 25 % of the total cases of PD surgery in a number of the larger pancreas treatment centers. The aim of this review is to provide an overview of management and outcome of vascular resection in PDAC surgery.
Similar content being viewed by others
References
Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254(2):311–9
Hackert T, Büchler MW (2013) Pancreatic cancer: advances in treatment, results and limitations. Dig Dis 31(1):51–6
Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT et al (2004) Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 99:492–501
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247(3):456–62
Birkmeyer JD, Siewers AE, Finlayson EV et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346(15):1128–1137
McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, Anderson FA, Tseng JF (2007) Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 246(2):246–53
Hackert T, Büchler MW, Werner J (2009) Surgical options in the management of pancreatic cancer. Minerva Chir 64(5):465–76
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 1.2008 and 1.2014. Available from http://www.nccn.org
Hackert T, Tjaden C, Büchler MW (2014) Developments in pancreatic surgery during the past ten years. Zentralbl Chir 139(3):292–300
Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, International Study Group of Pancreatic Surgery et al (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155(6):977–88
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, International Study Group on Pancreatic Surgery et al (2014) Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1):1–14
Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, Song SY (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923–929
Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE (2012) Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 7:28
Fortner JG (1973) Regional resection of cancer of the pancreas: a new surgical approach. Surgery 73:307–320
Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB (1996) Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 223:154–162
Harrison LE, Klimstra DS, Brennan MF (1996) Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 224:342–347
Müller SA, Hartel M, Mehrabi A et al (2009) Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 13:784–92
Kim PT, Wei AC, Atenafu EG, Cavallucci D, Cleary SP, Moulton CA, Greig PD, Gallinger S, Serra S, McGilvray ID (2013) Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma. Br J Surg 100(10):1349–56
Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT (2006) Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 10:1106–1115
Hartel M, Niedergethmann M, Farag-Soliman M, Sturm JW, Richter A, Trede M, Post S (2002) Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 168:707–712
Sasson A, Hoffmann J, Ross E et al (2002) En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 6:147–158.51
Siriwardana H, Siriwardena A (2006) Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 93:662–673
Weitz J, Kienle P, Schmidt J et al (2007) Portal vein resection for advanced pancreatic head cancer. J Am Coll Surg 204:712–6
Zhou Y, Zhang Z, Liu Y, Li B, Xu D (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 36(4):884–91
Sindelar WF (1989) Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 124:127–132
Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, Debus J, Jäger D, Büchler MW, Werner J (2012) Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery 152(3 Suppl 1):S33–42
Weitz J, Rahbari N, Koch M, Buchler MW (2010) The “artery first” approach for resection of pancreatic head cancer. J Am Coll Surg 210:e1–4
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, Weitz J (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 254(6):882–93
Chua TC, Saxena A (2010) Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 14(9):1442–52
Hackert T, Stampfl U, Schulz H, Strobel O, Büchler MW, Werner J (2011) Clinical significance of liver ischaemia after pancreatic resection. Br J Surg 98:1760–1765
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Luketina, R.R., Hackert, T. & Büchler, M.W. Vascular Resection in Pancreatic Cancer. Indian J Surg 77, 381–386 (2015). https://doi.org/10.1007/s12262-015-1364-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-015-1364-y